Answers are grounded in this paper and cite their sources.
L-arginase-based enzyme therapy, which depletes L-arginine by converting it to L-ornithine and urea, selectively inhibits the growth of L-arginine-dependent cancer cells with low toxicity. This approach shows promise as a novel cancer treatment. This research used Response Surface Methodology (RSM) to enhance L-arginase production by Alcaligenes aquatilis BC2, which was isolated from an Ethiopian soda lake. The Plackett-Burman Design was used to screen eight factors that influence L-arginase production and identified arginine concentration, peptone concentration, and incubation temperature as the most significant variables. The central composite design analysis demonstrated that the optimized conditions of 1.75 % L-arginine concentration, 3 % peptone concentration, and an incubation temperature of 37.5 °C enhance L-arginase production from a baseline of 92.45 U/mL to an optimized yield of 288.79 U/mL. This represents a 3.1-fold increase under the optimized conditions. The model was developed based on 20 experimental runs, demonstrating excellent fit with R2 = 0.9974 and a significant F-value of 420.28 (p < 0.0001). Additionally, the lack-of-fit test was conducted and found to be non-significant (F-value = 4.18, p = 0.0714), further supporting the model's predictive strength. This investigation showed that applying statistical design to optimize fermentation conditions leads to increased production of L-arginase, thereby advancing enzyme-based therapeutic practices and highlighting statistical optimization as essential for bioprocess development.
No takes yet. Share an insight, caveat, or question.
Assega et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: